| survRM2: Comparing restricted mean survival time H Uno, L Tian, M Horiguchi, A Cronin, C Battioui, J Bell R package version, 1.0-3, 2020 | 40 | 2020 |
| Quantification of long-term survival benefit in a comparative oncology clinical study M Horiguchi, L Tian, H Uno, SC Cheng, DH Kim, D Schrag, LJ Wei JAMA oncology 4 (6), 881-882, 2018 | 25 | 2018 |
| A flexible and coherent test/estimation procedure based on restricted mean survival times for censored time‐to‐event data in randomized clinical trials M Horiguchi, AM Cronin, M Takeuchi, H Uno Statistics in medicine 37 (15), 2307-2320, 2018 | 22 | 2018 |
| On permutation tests for comparing restricted mean survival time with small sample from randomized trials M Horiguchi, H Uno Statistics in Medicine 39 (20), 2655-2670, 2020 | 18 | 2020 |
| How do the accrual pattern and follow‐up duration affect the hazard ratio estimate when the proportional hazards assumption is violated? M Horiguchi, MJ Hassett, H Uno The Oncologist 24 (7), 867-871, 2019 | 14 | 2019 |
| Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab as a Result of Adverse Events Lived Significantly Longer Than Patients Who Continued … M Horiguchi, H Uno, LJ Wei Journal of Clinical Oncology: Official Journal of the American Society of …, 2018 | 14 | 2018 |
| survRM2: Comparing Restricted Mean Survival Time, 2017 H Uno, L Tian, A Cronin, C Battioui, M Horiguchi URL https://CRAN. R-project. org/package= survRM2. R package version, 1.0-2, 2017 | 13 | 2017 |
| Familial burden and other clinical factors associated with various types of cancer in individuals with lynch syndrome LH Biller, M Horiguchi, H Uno, C Ukaegbu, S Syngal, MB Yurgelun Gastroenterology 161 (1), 143-150. e4, 2021 | 10 | 2021 |
| Statistical test/estimation methods used in contemporary phase III cancer randomized controlled trials with time‐to‐event outcomes H Uno, M Horiguchi, MJ Hassett The oncologist 25 (2), 91-93, 2020 | 10 | 2020 |
| Comparison of colorectal and endometrial microsatellite instability tumor analysis and Premm5 risk assessment for predicting pathogenic germline variants on multigene panel testing A Mannucci, CS Furniss, C Ukaegbu, M Horiguchi, T Fehlmann, H Uno, ... Journal of Clinical Oncology 38 (34), 4086, 2020 | 9 | 2020 |
| Evaluating Noninferiority With Clinically Interpretable Statistics for the PROSELICA Study to Assess Treatment Efficacy of a Reduced Dose of Cabazitaxel for Treating Metastatic … M Horiguchi, H Uno, LJ Wei Journal of Clinical Oncology: Official Journal of the American Society of …, 2018 | 8 | 2018 |
| Development and validation of the PREMMplus model for multigene hereditary cancer risk assessment MB Yurgelun, H Uno, CS Furniss, C Ukaegbu, M Horiguchi, A Yussuf, ... Journal of Clinical Oncology 40 (35), 4083, 2022 | 7 | 2022 |
| Vascular injury markers associated with cognitive impairment in people with HIV on suppressive antiretroviral therapy D Guha, V Misra, J Yin, M Horiguchi, H Uno, D Gabuzda AIDS 37 (14), 2137-2147, 2023 | 6 | 2023 |
| Ratio and difference of average hazard with survival weight: new measures to quantify survival benefit of new therapy H Uno, M Horiguchi Statistics in Medicine 42 (7), 936-952, 2023 | 5 | 2023 |
| Package ‘survRM2’. June 13, 2020 H Uno, L Tian, M Horiguchi, A Cronin, C Battioui, J Bell | 5 | 2020 |
| Issues of the hazard ratio estimate and application of the restricted mean survival time to a non-inferiority study (New Advances in Statistical Inference and Its Related Topics) M Horiguchi, K Pak, M Mikami, M Takeuchi RIMS Kokyuroku 1954, 1-14, 2015 | 4* | 2015 |
| On assessing survival benefit of immunotherapy using long‐term restricted mean survival time M Horiguchi, L Tian, H Uno Statistics in Medicine 42 (8), 1139-1155, 2023 | 3 | 2023 |
| Package ‘survRM2’ H Uno, L Tian, M Horiguchi, A Cronin, C Battioui, J Bell, MH Uno | 3 | 2022 |
| Interpreting the Benefit of Trifluridine/Tipiracil in Metastatic Colorectal Cancer With Respect to Progression-Free Survival and Overall Survival. R Sun, M Horiguchi, LJ Wei Journal of Clinical Oncology: Official Journal of the American Society of …, 2018 | 3 | 2018 |
| Overall survival in the randomized phase II study investigating pazopanib versus weekly paclitaxel in relapsed or progressive urothelial cancer M Horiguchi, H Uno, LJ Wei Journal of Clinical Oncology 35 (29), 3373-3373, 2017 | 3 | 2017 |
